{"denoms":[{"counts":[{"groupId":"BG000","value":"143"},{"groupId":"BG001","value":"144"},{"groupId":"BG002","value":"287"}],"units":"Participants"}],"groups":[{"description":"Participants received docetaxel 75 milligram per squared meters (mg/m\\^2) administered intravenously on Day 1 of each 21 day cycle until disease progression or unacceptable toxicity or death.","id":"BG000","title":"Docetaxel"},{"description":"Participants were administered atezolizumab intravenously on Day 1 of each 21 day cycle at a fixed dose of 1200 mg. Atezolizumab treatment were to continued as long as participants were experiencing clinical benefit as assessed by the investigator.","id":"BG001","title":"Atezolizumab"},{"description":"Total of all reporting groups","id":"BG002","title":"Total"}],"measures":[{"classes":[{"categories":[{"measurements":[{"groupId":"BG000","spread":"9.4","value":"61.8"},{"groupId":"BG001","spread":"9.2","value":"61.5"},{"groupId":"BG002","spread":"9.3","value":"61.6"}]}]}],"dispersionType":"STANDARD_DEVIATION","paramType":"MEAN","title":"Age, Continuous","unitOfMeasure":"years"},{"classes":[{"categories":[{"measurements":[{"groupId":"BG000","value":"67"},{"groupId":"BG001","value":"51"},{"groupId":"BG002","value":"118"}],"title":"Female"},{"measurements":[{"groupId":"BG000","value":"76"},{"groupId":"BG001","value":"93"},{"groupId":"BG002","value":"169"}],"title":"Male"}]}],"paramType":"COUNT_OF_PARTICIPANTS","title":"Sex: Female, Male","unitOfMeasure":"Participants"}],"populationDescription":"Intent to treat (ITT) population for efficacy analyses included all randomized participants, regardless of whether they received any study drug. In the efficacy analyses, the ITT population, participants were grouped according to the treatment arm to which they were assigned."}